Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study

Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial

(2023) Ornella Verrastro et al.   LANCET

Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population

(2022) Joana Rigor et al.   POSTGRADUATE MEDICINE

Ultrasonographic index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease

(2022) Jeong Woo Kim et al.   Quantitative Imaging in Medicine and Surgery

Accuracy of FIB-4 to Detect Elevated Liver Stiffness Measurements in Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study in Referral Centers

(2022) Mauro Viganò et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

(2022) Michael H. Le et al.   Clinical and Molecular Hepatology

Preparing for the NASH Epidemic: A Call to Action

(2021) Fasiha Kanwal et al.   GASTROENTEROLOGY

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease

(2021) Fasiha Kanwal et al.   GASTROENTEROLOGY

FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran

(2021) Behnaz Amernia et al.   BMC GASTROENTEROLOGY

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

(2021) Ramy Younes et al.   JOURNAL OF HEPATOLOGY

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

(2020) Rod S. Taylor et al.   GASTROENTEROLOGY

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials

(2020) Beth A. Davison et al.   JOURNAL OF HEPATOLOGY

The correct formula to calculate triglyceride-glucose index (TyG)

(2020) Javad Alizargar et al.   JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM

NAFLD as a continuum: from obesity to metabolic syndrome and diabetes

(2020) Amélio F. Godoy-Matos et al.   Diabetology & Metabolic Syndrome

A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study

(2020) Stephen A Harrison et al.   Lancet Gastroenterology & Hepatology

The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective

(2020) Amr Dokmak et al.   AMERICAN JOURNAL OF MEDICINE

Non-Invasive Assessment of Liver Disease in Patients with NAFLD

(2019) Laurent Castera et al.   GASTROENTEROLOGY

Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia

(2019) Miquel Serra-Burriel et al.   JOURNAL OF HEPATOLOGY

Triglyceride/glucose index is a reliable alternative marker for insulin resistance in South American overweight and obese children and adolescents

(2019) João Carlos Locateli et al.   JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM

Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers

(2018) Eduardo Vilar-Gomez et al.   JOURNAL OF HEPATOLOGY

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

(2017) Chris Estes et al.   HEPATOLOGY

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

(2017) Parambir S. Dulai et al.   HEPATOLOGY

The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease

(2017) Shujun Zhang et al.   Lipids in Health and Disease

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Fasting Triglycerides and Glucose Index as a Diagnostic Test for Insulin Resistance in Young Adults

(2016) Fernando Guerrero-Romero et al.   ARCHIVES OF MEDICAL RESEARCH

Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease

(2014) L. Fedchuk et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

(2014) Munkhzul Otgonsuren et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

(2013) Quentin M. Anstee et al.   Nature Reviews Gastroenterology & Hepatology

A simple index of lipid overaccumulation is a good marker of liver steatosis

(2010) Giorgio Bedogni et al.   BMC GASTROENTEROLOGY

The Product of Triglycerides and Glucose, a Simple Measure of Insulin Sensitivity. Comparison with the Euglycemic-Hyperinsulinemic Clamp

(2010) Fernando Guerrero-Romero et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System for Nonalcoholic Fatty Liver Disease

(2010) Ravi Juluri et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors

(2009) Anna Kotronen et al.   GASTROENTEROLOGY

The Product of Fasting Glucose and Triglycerides As Surrogate for Identifying Insulin Resistance in Apparently Healthy Subjects

(2008) Luis E. Simental-Mendía et al.   Metabolic Syndrome and Related Disorders